The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making ...

The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug ...

The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are ...

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration said Eli Lilly's popular weight-loss drugs ...

The $4.5 billion investment will create the Lilly Medicine Foundry, a center that will combine research and manufacturing ...

Pharmaceutical giant Eli Lilly (LLY) is putting $4.5 billion toward building a new site to develop and manufacture drugs.

Blockbuster drugs Zepbound and Mounjaro have come off the FDA's shortage list. Shares of Hims & Hers, which had capitalized ...

GLP-1 weight-loss drugs Mounjaro and Zepbound have been removed from the Food and Drug Administration's (FDA) shortage list. ...

The roadmap suggests those with the greatest clinical need will get priority access, according to the NHS national medical ...